Shire subsidiaries settled litigation with Actavis and Watson Laboratories
Pharmaceuticals group Shire has said its subsidiary Shire LLC, has settled all pending litigation with Actavis and Watson Laboratories.
Pharmaceuticals group Shire has said its subsidiary Shire LLC, has settled all pending litigation with Actavis and Watson Laboratories.
The litigation was in relation Actavis and Watson's abbreviated new drug applications (ANDAs) for generic versions of Shire's Intuniv product for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The settlement provides Actavis with a licence to make and market its generic versions of Intuniv in the US on December 1st 2014, and any sales will results in royalty payments of 25% of gross profits to Shire during the 180 day exclusivity period.
The settlement also provides Watson with a licence to make and market Watson's generic versions of Intuniv in the US 181 days after Actacis's own launch.
NR